Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.
Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.
Diversity, equity, and inclusion (DE&I) initiatives have become increasingly important for attracting diverse perspectives, improving problem solving and advancing innovation in companies.
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.
Porelio's FOMS adsorbents target PFAS, metals, and genotoxins, outperforming commercial solutions with unmatched selectivity, innovation, and sustainability.
The pharmaceutical industry requires reliable and innovative partners who can flexibly adapt to its changing demands.
The EU Green Deal has hurt Europe's industry. The Clean Industrial Deal aims to improve this, but a change of mindset at the Commission is needed.
Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.
BASF and Braven Environmental, a market leader in advanced recycling, have signed a supply agreement for Braven PyChem. This recycled feedstock, derived from mixed plastic waste, will partially replace fossil resources at the BASF TotalEnergies Petrochemical (BTP) facility in Port Arthur, Texas, US, the companies said. Under the agreement, Braven will supply BASF from a multi-unit facility that it plans to build in Texarkana, Texas.
Indian generic drug maker Sun Pharma agreed to acquire US immunotherapy and targeted oncology company Checkpoint Therapeutics for an upfront value of $355 million. The transaction is expected to be completed in the second quarter of 2025 and is subject to customary closing conditions.
Syngene, a global contract research, development, and manufacturing organization (CRDMO), recently announced the acquisition of its first biologics site in the USA – fitted with multiple monoclonal antibody (mAbs) manufacturing lines.
Axplora, an API small molecule and ADC (antibody-drug conjugate) manufacturer, is strengthening its position in the commercial manufacturing ADCs by launching a cutting-edge payload manufacturing workshop at its Le Mans site (France).
German contract development and manufacturing organization (CDMO) Adragos Pharma has completed a €4 million project to install and commission a new, cGMP-compliant liquid drug filling line and associated cartoning machine at its plant in Leipzig, Germany.
Rio Tinto has completed the $6.7 billion acquisition of Arcadium Lithium and is now the parent company of Arcadium Lithium, which will be renamed Rio Tinto Lithium and will also include the Rincon Lithium Project.
Ireland’s Jazz Pharmaceuticals signed an agreement to acquire its compatriot Chimerix for approximately $935 million. The transaction is expected to close in the second quarter of 2025.
Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.
OMV and ADNOC agreed to combine their Borealis and Borouge shareholdings into Borouge Group International. ADNOC has also signed a share purchase agreement with Nova Chemicals, an indirect wholly owned subsidiary of Mubadala Investment Company, to acquire 100% of Nova Chemicals for an enterprise value of $13.4 billion. In addition, ADNOC and OMV have agreed for Borouge Group International to take over Nova Chemicals after closing.
WE Soda has acquired Genesis Alkali (Alkali), the largest US-based producer of natural soda ash, from Genesis Energy in an all-cash transaction for $1.425 billion.
The US pharmaceutical giant AbbVie and Danish biotechnology company Gubra, specializing in preclinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, signed a license agreement to develop GUB014295, a potential best-in-class, long-acting amylin analog for the treatment of obesity.
Toray Industries has opened the Toray Taiwan Technical Center. This new facility aims to enhance research and development in advanced semiconductor technologies and materials, and provide technical services in the Taiwan market, which plays a significant role in the global semiconductor supply chain.
Dutch start-up Mavisol has developed an innovative machine vision and AI solution designed specifically for plastic converters, with the aim of promoting environmental sustainability and improving material reuse efficiency.
Eli Lilly plans to invest $27 billion to bolster its domestic medicine production across several therapeutic areas by building four new manufacturing sites in the US.
The 15% capacity expansion of Arkema’s PVDF production site in Calvert City, Kentucky, represents an investment of approximately $20 million (€19 million).
Ahead of the unveiling of the EU’s Clean Industrial Deal, Ineos Chairman and CEO, Sir Jim Ratcliffe, authored an open letter to emphasize the importance of supportive political decisions and measures for the European industry. Releasing the open letter, Ineos stated: “A year on from the signing of ‘The Antwerp Declaration for a European Industrial Deal’ we have not seen the action necessary to stem the decline of European industry. Ineos has continued to invest in Europe; however, it is now an exception in a landscape of deindustrialization and closures.” Please read the complete open letter below:
Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.
As part of a review initiated by Air Products’ newly-elected board of directors and CEO, the company decided to exit three projects in the US. As a result, Air Products expects to record a pre-tax charge not to exceed $3.1 billion in its fiscal 2025 second quarter, primarily to write down assets and terminate contractual commitments.
German flavor and fragrance company Symrise has signed a strategic partnership with Hofseth BioCare (HBC), a Norwegian manufacturer of salmon-based ingredients for the human health and pet nutrition markets. With this partnership, Symrise wants to expand its presence in the health sector with clinically proven marine ingredients, the company said.
BASF India Ltd. has broken ground on a new plant to increase the production capacity of its Cellasto microcellular polyurethane (MCU) in Dahej, India.
Nouryon plans to expand its chromatography media manufacturing facility in Bohus, Sweden, doubling the site’s capacity. Construction will begin in early 2025, and the start of production is expected in early 2027, the company said.
Henkel recently announced the opening of its new Application Center in Busan, South Korea, marking a significant investment in the global sports & fashion industry.
US investment company Pritzker Private Capital (PPC) has agreed to acquire a majority stake in Americhem, a family-owned US manufacturer of custom color masterbatch, performance additive and engineered compound solutions.
US-based biotechnology company FibroGen announced the sale of its China subsidiary to AstraZeneca for approximately $160 million.
Following completion of the required social and corporate procedures, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R).
The Global Impact Coalition (GIC), a CEO-led collaborative platform originally incubated at the World Economic Forum, launches the world’s first Automotive Plastics Circularity pilot together with seven global leaders in the chemical and recycling industries.
